Validation of Progranulin as a Biomarker for Sepsis (PROGRANULIN)

Ludwig Maximilian University of Munich

Status: Completed

Conditions: Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT03280576

Progranulin_1

Details and patient eligibility

About

Progranulin blood concentrations in patients with sepsis will be analysed in relation to disease status in order to validate progranulin as a biomarker for sepsis. Patients undergoing cardiac surgery will serve as controls.

Full description

Single nucleotide polymorphisms with known effects on Progranulin plasma concentrations will be assessed in a separate analysis. Expression levels of microRNAs isolated from plasma, circulating exosomes and blood cells will be determined by next-generation sequencing to characterize epigenetic influences on progranulin plasma levels.

Enrollment: 556 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Sepsis or Septic Shock defined according to SEPSIS-3 criteria - Age > 18 years

Exclusion criteria

• No informed consent
• Age < 18 years
• Pregnancy
• Immunosuppression (including transplantation)
• Charlson Comorbidity Index > 0 (healthy volunteers)

Trial design

556 participants in 3 patient groups

Sepsis

Description:

Patients with sepsis

Cardiac Surgery

Description:

Patients undergoing cardiac surgery

Healthy controls

Description:

Normal individuals